Citi says this shoe stock can gain more than 20% thanks to its ‘resilient business model’
Citi thinks it’s time to buy Steven Madden shares.
Citi upgrades Merck, says the pharma giant’s drug pipeline is underappreciated
Citi upgraded Merck shares to buy and raised its price target to $130. The firm believes that Merck’s drug pipeline is underappreciated by the market.
Bloomberg plans to integrate GPT-style A.I. into its terminal
Bloomberg says its internal AI model can more accurately answer questions, assess whether headlines are bearish or bullish, and even write headlines.
Delta Air Lines posts quarterly loss but forecasts profit as peak travel season approaches
Delta forecast revenue growth and adjusted profit for the second quarter that were ahead of analysts’ estimates.
Deutsche Bank downgrades this solar energy stock, says it’s expensive after surging nearly 40%
Analyst Corinne Blanchard downgraded the stock to hold from buy. Blanchard noted that it’s is expensive after rallying 39% this year and 42% since November.
Europe should make its A.I. regulations more sweeping, prominent experts urge
The experts advocate for Europe to include general purpose AI in its regulations, rather than a more narrow definition of high-risk AI.
Sen. Dianne Feinstein faces first calls to resign from members of Congress
Democratic Reps. Ro Khanna and Dean Phillips said Feinstein needs to step down, as her lengthy absence from the Senate could imperil Democrats’ ability to confirm more judges.
ChatGPT may be able to predict stock movements, finance professor shows
Alejandro Lopez-Lira, a finance professor at the University of Florida, used ChatGPT to parse news headlines for whether they’re good or bad for a stock.
Wharton’s Jeremy Siegel says it may be a rough 3 to 6 months for stocks
Jeremy Siegel believes the Federal Reserve has gone too far with its rate hikes, making a recession and downturn in equities imminent later this year.
House Democrats call for immediate hearing on Texas abortion pill ruling
All 23 House Democrats on the Commerce committee noted in a letter that the abortion pill ruling undermines the FDA’s authority over the drug-approval process.
